About Cyndi Root

Cyndi Root is a contributing writer for Life Science Connect who writes regular life sciences news features for several markets. She has a Bachelor’s degree from Yale University.

ARTICLES BY CYNDI ROOT

  • Thomson Reuters Recognizes World Hepatitis Day With Report On HCV Drugs Thomson Reuters has prepared a report and an infographic on the Hepatitis drug market in recognition of World Hepatitis Day. The data and commentary highlights the drug classes used against hepatitis C virus (HCV), the state of HCV drug development, and the industry players boasting new drugs — including Gilead’s Sovaldi, Roche’s mericitabine, and Bristol-Myers Squibb’s daclatasvir- based therapies. Also addressed are the costs of the new drugs, which have shocked insurance companies, patients, and legislators.
  • Merck KGaA Targets Chinese Market, Builds New Shanghai Manufacturing Facility

    Merck KGaA announced in a press release that it is strengthening its commitment to the Chinese market as part of its overall strategy to target emerging markets.

  • Hikma Acquires Ben Venue Generic Injectables Manufacturing Facility In Ohio

    Hikma Pharmaceuticals PLC announced in a press release that it has acquired the Ben Venue Laboratories manufacturing facility in Bedford, OH. Ben Venue is part of Boehringer Ingelheim, and its generic injectables manufacturing site includes four manufacturing plants and a Quality and Development Centre (QDC).

  • Weekly FDA Enforcement Report For Drugs And Biologics 7/16/14

    The Food and Drug Administration (FDA) has released its Drug and Biological product Enforcement Report for July 16, 2014. The agency publicizes recalls in its weekly report as press releases are not issued for all recalls. Manufacturers issue recalls voluntarily or the FDA initiates the action. View the recalls by Biologics or Drugs and by Classification. 

  • Weekly FDA Enforcement Report For Drugs And Biologics 7/9/14 The Food and Drug Administration (FDA) has released its Drug and Biological product Enforcement Report for July 9, 2014. The agency publicizes recalls in its weekly report as press releases are not issued for all recalls. Manufacturers issue recalls voluntarily or the FDA initiates the action. View the recalls by Biologics or Drugs, and by Classification.
  • NIH, NSF Collaborate To Find Markets For Biomedical Research Innovations

    The National Institutes of Health (NIH) announced in a press release that it will provide its researchers training, in collaboration with the National Science Foundation (NSF), to evaluate biomedical innovations for commercial potential. I-Corps instructors with biomedical business experience will work closely with federally funded personnel with the goal of turning NIH innovations into applied health technologies. Slated to participate in the pilot program are award grantees from NIH institutes, including the National Cancer Institute (NCI). Michael Weingarten Director of the NCI SBIR Development Center, said, “I-Corps will help teach NIH-funded start-ups how to build scalable business models around new technologies they’re developing for the detection and treatment of disease.”

  • NIH Awards Sorrento $2.6 Million For Bispecific Antibodies Sorrento Therapeutics announced in a press release that the National Institutes of Health (NIH) has provided funding for the development of bispecific antibodies. Two small business grants from the NIH will allow Sorrento to use its antibody conjugation technology platform to develop antibodies for two of the NIH’s anti-bacterial immunotherapies. Sorrento's pipeline also shows promise in anti-infectives and auto-immune diseases.
  • Boston Strategics Licenses E6201 Oncology Drug From Eisai Boston Strategics Corporation (BSC) announced in a press release that it has entered a licensing agreement with Eisai. The new partnership allows BSC to develop and commercialize Eisai’s E6201, an oncology drug, worldwide.
  • Gilead Seeks New Indication In Japan For Sovaldi In Genotype 2 HCV

    Gilead Sciences announced in a press release it has requested that the Pharmaceutical and Medical Devices Agency (PMDA) of Japan approve its New Drug Application (NDA) for Sovaldi (sofosbuvir). The nucleotide analog polymerase inhibitor treats chronic hepatitis C virus (HCV) infection. Gilead’s NDA is for sofosbuvir with ribavirin (RBV) in patients with genotype 2 HCV infection. The NDA is Gilead’s first in Japan and if approved, Sovaldi would be the first drug marketed by Gilead in Japan.

  • Weekly FDA Enforcement Report For Drugs And Biologics 6/18/14

    The Food and Drug Administration (FDA) has released its Drug and Biological product Enforcement Report for June 18, 2014. The agency publicizes recalls in its weekly report as press releases are not issued for all recalls. Manufacturers issue recalls voluntarily or the FDA initiates the action. View the recalls by Biologics or Drugs, and by Classification. 

More From Cyndi Root
Newsletter Signup
Newsletter Signup